Latest Breaking News On - Gynecological oncological trial - Page 1 : comparemela.com

Aravive (ARAV) Reports Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept

Aravive (ARAV) Reports Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCorey davisGail mcintyreKatherine fuhProduct development awardCancer prevention research institute of texasCompany annual report on formPh dlifesci advisorsEuropean network for gynecological oncological trialEuropean commissionDivision of gynecologic oncologyAravive incFoundation incChief executiveAssociate professorEuropean network

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCorey davisKatherine fuhGail mcintyreEuropean commissionProduct development awardPh dlifesci advisorsDivision of gynecologic oncologyCompany annual report on formAravive incFoundation incEuropean network for gynecological oncological trialCancer prevention research institute of texasChief executiveAssociate professorEuropean network

Pembrolizumab plus chemoradiotherapy extends PFS in advanced cervical cancer

Pembrolizumab plus chemoradiotherapy extends PFS in advanced cervical cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Pembrolizumab keytrudaDomenica lorussoCatholic university of romeEuropean network for gynecological oncological trialEuropean networkGynecological oncological trialCatholic university

Dostarlimab Plus Chemotherapy Shows Survival Benefit, Fills Unmet Need for Patients With Recurrent Endometrial Cancer

Combining the immune checkpoint inhibitor dostarlimab-gxly with standard-of-care chemotherapy elicited an increase in progression-free survival rates compared with chemotherapy alone for patients with primary advanced or recurrent endometrial cancer.

Mansoor raza mirzaCopenhagen university hospitalNordic society of gynecologic oncologyEuropean network for gynecological oncological trialDepartment of oncologySociety of gynecological oncologyGynecologic oncology groupGynecological oncologyAnnual meetingNordic societyGynecologic oncologyEuropean networkGynecological oncological trialGyneologic oncology annual meetingImmune checkpoint inhibitorDostarlimab gxly jemperli

Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript

CORT earnings call for the period ending December 31, 2021.

United statesNew jerseyCanaccord genuityChris howerton jefferiesMatt kaplanCharles robbMichelle gilsonCharlie robbAtabak mokariGreg fraser truistMatt kaplan ladenburg thalmannAmerica merrill lynchChris howertonMichelle gilson canaccord genuityJoseph belanoffGreg fraser